PDA

View Full Version : Human Genome Sciences And GSK Announce FDA Priority Review Designation For Benlysta(R



RSS Bot
08-20-2010, 07:05 AM
Human Genome Sciences, Inc. (Nasdaq: HGSI) and GlaxoSmithKline PLC (GSK) today announced that the U.S. Food and Drug Administration (FDA) has granted a priority review designation to BENLYSTAŽ (belimumab) as a potential treatment for systemic lupus erythematosus (SLE)...

More... (http://mnt.to/f/3HFm)